drug · protein

SYNAREL

updated 3mo ago

by $PFE PFIZER INC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Protein drug with a maximum clinical stage of Approval, with an approval for endometriosis.

targets

Gonadotropin-releasing hormone receptor

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

SYNAREL

trade names

Synarel

generic

NAFARELIN ACETATE

MOA

Gonadotropin-releasing hormone receptor agonist

indication

INDICATIONS AND USAGE FOR CENTRAL PRECOCIOUS PUBERTY (For Endometriosis, See Reverse Side ) SYNAREL is indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes. The diagnosis of central precocious puberty (CPP) is suspected when premature development of secondary sexual characteristics occurs at or before the age of 8 years in girls and 9 years in boys, and is accompanied by significant advancement of bone age and/or a poor adult height prediction. The diagnosis should be confirmed by pubertal gonadal sex steroid levels and a pubertal LH response to stimulation by native GnRH. Pelvic ultrasound assessment in girls usually reveals enlarged uterus and ovaries, the latter often with multiple cystic formations. Magnetic resonance imaging or CT-scanning of the brain is recommended to detect hypothalamic or pituitary tumors, or anatomical changes associated with increased intracranial pressure. Other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders must be excluded by proper clinical hormonal and diagnostic imaging examinations.

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 27m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · protein

save

SYNAREL

updated 3mo ago

by $PFE PFIZER INC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Protein drug with a maximum clinical stage of Approval, with an approval for endometriosis.

targets

Gonadotropin-releasing hormone receptor

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

SYNAREL

trade names

Synarel

generic

NAFARELIN ACETATE

MOA

Gonadotropin-releasing hormone receptor agonist

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 27m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

SYNAREL

🐶 often sniffed alongside

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

SYNAREL

🐶 often sniffed alongside

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)